GlobeStar Therapeutics Corporation (GSTC)
USD 0.0
(-16.67%)
USD 0.0
(-16.67%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 359.71 Thousand USD | 1698.55% |
| 2022 | 20 Thousand USD | -81.16% |
| 2021 | 106.13 Thousand USD | -31.56% |
| 2020 | 155.07 Thousand USD | 36.28% |
| 2019 | 113.79 Thousand USD | -60.11% |
| 2018 | 285.28 Thousand USD | 221.29% |
| 2017 | 88.79 Thousand USD | -83.01% |
| 2016 | 522.74 Thousand USD | 373.97% |
| 2015 | 110.29 Thousand USD | -57.02% |
| 2014 | 256.6 Thousand USD | 236.48% |
| 2013 | 76.26 Thousand USD | -76.82% |
| 2012 | 329.05 Thousand USD | 1075.18% |
| 2011 | 28 Thousand USD | 0.0% |
| 2010 | - USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q3 | 329.04 Thousand USD | 0.19% |
| 2024 Q1 | 368.67 Thousand USD | 2.49% |
| 2024 Q2 | 328.4 Thousand USD | -10.92% |
| 2023 FY | 359.71 Thousand USD | 1698.55% |
| 2023 Q2 | 59.65 Thousand USD | 198.25% |
| 2023 Q3 | 15.87 Thousand USD | -73.38% |
| 2023 Q4 | 359.71 Thousand USD | 2165.46% |
| 2023 Q1 | 20 Thousand USD | 0.0% |
| 2022 Q2 | 20 Thousand USD | -92.51% |
| 2022 FY | 20 Thousand USD | -81.16% |
| 2022 Q4 | 20 Thousand USD | 0.0% |
| 2022 Q1 | 266.88 Thousand USD | 151.47% |
| 2022 Q3 | 20 Thousand USD | 0.0% |
| 2021 Q4 | 106.13 Thousand USD | 19.63% |
| 2021 FY | 106.13 Thousand USD | -31.56% |
| 2021 Q2 | 118.98 Thousand USD | -23.36% |
| 2021 Q1 | 155.26 Thousand USD | 0.12% |
| 2021 Q3 | 88.71 Thousand USD | -25.44% |
| 2020 Q4 | 155.07 Thousand USD | 37.01% |
| 2020 FY | 155.07 Thousand USD | 36.28% |
| 2020 Q3 | 113.19 Thousand USD | 24.46% |
| 2020 Q2 | 90.94 Thousand USD | -21.34% |
| 2020 Q1 | 115.61 Thousand USD | 1.6% |
| 2019 Q1 | 229.41 Thousand USD | -19.58% |
| 2019 Q3 | 171 Thousand USD | -34.26% |
| 2019 Q4 | 113.79 Thousand USD | -33.45% |
| 2019 Q2 | 260.1 Thousand USD | 13.38% |
| 2019 FY | 113.79 Thousand USD | -60.11% |
| 2018 Q2 | 185.88 Thousand USD | 20.87% |
| 2018 Q4 | 285.28 Thousand USD | 42.98% |
| 2018 Q1 | 153.79 Thousand USD | 73.2% |
| 2018 FY | 285.28 Thousand USD | 221.29% |
| 2018 Q3 | 199.52 Thousand USD | 7.34% |
| 2017 Q2 | 550.83 Thousand USD | 9.08% |
| 2017 FY | 88.79 Thousand USD | -83.01% |
| 2017 Q3 | 602.46 Thousand USD | 9.37% |
| 2017 Q1 | 504.99 Thousand USD | 0.0% |
| 2017 Q4 | 88.79 Thousand USD | -85.26% |
| 2016 Q1 | 153.27 Thousand USD | 38.98% |
| 2016 Q2 | 279.9 Thousand USD | 82.61% |
| 2016 Q4 | - USD | -100.0% |
| 2016 FY | 522.74 Thousand USD | 373.97% |
| 2016 Q3 | 424.49 Thousand USD | 51.66% |
| 2015 Q1 | 297.02 Thousand USD | 15.75% |
| 2015 Q3 | 266.8 Thousand USD | 23.85% |
| 2015 Q2 | 215.42 Thousand USD | -27.47% |
| 2015 FY | 110.29 Thousand USD | -57.02% |
| 2015 Q4 | 110.29 Thousand USD | -58.66% |
| 2014 FY | 256.6 Thousand USD | 236.48% |
| 2014 Q4 | 256.6 Thousand USD | 0.97% |
| 2014 Q3 | 254.14 Thousand USD | 62.92% |
| 2014 Q2 | 155.99 Thousand USD | -4.2% |
| 2014 Q1 | 162.83 Thousand USD | 113.52% |
| 2013 Q1 | 22.3 Thousand USD | -93.22% |
| 2013 Q2 | 13.36 Thousand USD | -40.08% |
| 2013 Q3 | 39 Thousand USD | 191.87% |
| 2013 Q4 | 76.26 Thousand USD | 95.53% |
| 2013 FY | 76.26 Thousand USD | -76.82% |
| 2012 Q2 | 423.84 Thousand USD | 508.34% |
| 2012 FY | 329.05 Thousand USD | 1075.18% |
| 2012 Q4 | 329.05 Thousand USD | -37.31% |
| 2012 Q3 | 524.92 Thousand USD | 23.85% |
| 2012 Q1 | 69.67 Thousand USD | 148.83% |
| 2011 Q3 | 25 Thousand USD | 0.0% |
| 2011 Q2 | - USD | 0.0% |
| 2011 Q1 | - USD | 0.0% |
| 2011 FY | 28 Thousand USD | 0.0% |
| 2011 Q4 | 28 Thousand USD | 12.0% |
| 2010 FY | - USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 41.2 Million USD | 99.127% |
| Nanobac Pharmaceuticals, Incorporated | 4.12 Million USD | 91.273% |
| SQZ Biotechnologies Company | 27.47 Million USD | 98.691% |
| Evofem Biosciences, Inc. | 43.37 Million USD | 99.171% |
| Santhera Pharmaceuticals Holding AG | 29.76 Million USD | 98.792% |
| Mesoblast Limited | 118.7 Million USD | 99.697% |
| Propanc Biopharma, Inc. | 948.27 Thousand USD | 62.067% |
| Genus plc | 233.1 Million USD | 99.846% |
| VioQuest Pharmaceuticals, Inc. | 2.93 Million USD | 87.725% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | 73.228% |
| Marizyme, Inc. | 18.71 Million USD | 98.078% |
| ContraFect Corporation | 2.88 Million USD | 87.514% |
| Nymox Pharmaceutical Corporation | 750 Thousand USD | 52.039% |
| PsyBio Therapeutics Corp. | 135.48 Thousand USD | -165.494% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.44 Million USD | 75.129% |
| Intellipharmaceutics International Inc. | 2.32 Million USD | 84.535% |
| AXIM Biotechnologies, Inc. | 5.65 Million USD | 93.643% |
| MultiCell Technologies, Inc. | 202.58 USD | -177464.419% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 57.48 Million USD | 99.374% |
| EV Biologics, Inc. | 1.49 Million USD | 75.935% |
| Q BioMed Inc. | 4.1 Million USD | 91.248% |
| Emmaus Life Sciences, Inc. | 33.1 Million USD | 98.913% |
| Neon Bloom, Inc. | 630.07 Thousand USD | 42.91% |
| Mosaic ImmunoEngineering Inc. | 1.22 Million USD | 70.716% |
| Biomind Labs Inc. | 735.54 Thousand USD | 51.096% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 171.54 Million USD | 99.79% |
| Oncotelic Therapeutics, Inc. | 12.99 Million USD | 97.232% |
| Skye Bioscience, Inc. | 4.61 Million USD | 92.206% |
| Therapeutic Solutions International, Inc. | 888.06 Thousand USD | 59.495% |
| THC Farmaceuticals, Inc. | 141.51 Thousand USD | -154.18% |
| Arch Therapeutics, Inc. | 5.87 Million USD | 93.873% |
| IMV Inc. | 28.88 Million USD | 98.755% |
| Acro Biomedical Co., Ltd. | 25.71 Thousand USD | -1298.616% |
| Curative Biotechnology, Inc. | 2.25 Million USD | 84.072% |
| GB Sciences, Inc. | 1.75 Million USD | 79.554% |
| Alpha Cognition Inc. | 1.22 Million USD | 70.525% |
| HST Global, Inc. | 98.31 Thousand USD | -265.86% |
| CSL Limited | 12.18 Billion USD | 99.997% |
| Halberd Corporation | 150 Thousand USD | -139.807% |
| Enzolytics Inc. | 996.33 Thousand USD | 63.897% |
| Resverlogix Corp. | 6.49 Million USD | 94.458% |
| Affymax, Inc. | - USD | -Infinity% |
| SYBLEU INC | 477.5 Thousand USD | 24.668% |
| Nuo Therapeutics, Inc. | 255.59 Thousand USD | -40.736% |
| argenx SE | 20 Million USD | 98.201% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 45.56 Million USD | 99.21% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 86.72% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | - USD | -Infinity% |
| Zenith Capital Corp. | 10.22 Thousand USD | -3417.946% |
| Genscript Biotech Corporation | 417.73 Million USD | 99.914% |
| Ember Therapeutics, Inc. | 200.61 Thousand USD | -79.303% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.39 Million USD | 84.998% |
| WPD Pharmaceuticals Inc. | 229.29 Thousand USD | -56.879% |
| American Oriental Bioengineering, Inc. | 67.64 Million USD | 99.468% |
| Provectus Biopharmaceuticals, Inc. | 3.02 Million USD | 88.113% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | - USD | -Infinity% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.32 Million USD | 98.23% |
| Cotinga Pharmaceuticals Inc. | 148.65 Thousand USD | -141.978% |
| BioStem Technologies, Inc. | 4.71 Million USD | 92.365% |
| ONE Bio Corp. | 19.71 Million USD | 98.175% |
| Reve Technologies, Inc. | 250.18 Thousand USD | -43.779% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | 248.72 Thousand USD | -44.624% |
| Agentix Corp. | 50 Thousand USD | -619.42% |
| LadRx Corporation | 33.6 Thousand USD | -970.374% |
| Cell Source, Inc. | 9.25 Million USD | 96.113% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | 52.432% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | 52.432% |
| NovAccess Global Inc. | 2.19 Million USD | 83.649% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 94.914% |
| Itoco Inc. | 228.37 Thousand USD | -57.507% |
| Rasna Therapeutics, Inc. | 210.97 Thousand USD | -70.499% |
| Pathfinder Cell Therapy, Inc. | 4.98 Million USD | 92.781% |
| Kadimastem Ltd | 891.22 Thousand USD | 59.639% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | 10.486% |
| CytoDyn Inc. | 30.07 Million USD | 98.804% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | 484.28 Thousand USD | 25.723% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Qrons Inc. | 351.84 Thousand USD | -2.235% |
| Alseres Pharmaceuticals, Inc. | 7.81 Million USD | 95.4% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 122.5 Thousand USD | -193.641% |
| Rebus Holdings, Inc. | 310 Thousand USD | -16.035% |
| ImmunoCellular Therapeutics, Ltd. | 4.73 Million USD | 92.404% |
| International Stem Cell Corporation | 4.17 Million USD | 91.39% |
| Bioxytran, Inc. | 1.92 Million USD | 81.314% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -476.338% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | 83.506% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 8.31 Million USD | 95.674% |
| Adhera Therapeutics, Inc. | 8.58 Million USD | 95.81% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 1.55 Million USD | 76.875% |
| Innovation Pharmaceuticals Inc. | 268 Thousand USD | -34.22% |
| Neutra Corp. | 54.15 Thousand USD | -564.211% |
| Windtree Therapeutics, Inc. | 1.83 Million USD | 80.344% |
| PureTech Health plc | 25.51 Million USD | 98.59% |
| Coeptis Therapeutics, Inc. | 1.22 Million USD | 70.617% |
| IXICO plc | 472.02 Thousand USD | 23.794% |
| IntelGenx Technologies Corp. | 15.5 Million USD | 97.679% |
| Gelesis Holdings, Inc. | 62.26 Million USD | 99.422% |
| CSL Limited | 12.18 Billion USD | 99.997% |
| Cellectis S.A. | 92.77 Million USD | 99.612% |